Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901

AIM:To investigate the role of Ras association domain family protein 1 isoform A (RASSF1A) in gastric tumorigenesis. METHODS:Through over-expression of RASSF1A gene in the SGC7901 cell line which was induced by a lipofectamine-mediated gene transfer approach. Activator protein-1 (AP-1) DNA binding activity was measured by electrophoretic mobility shift assay (EMSA). RESULTS:Compared with the control clones, cells over- expressing RASSF1A exhibited significant inhibition of cell growth with G1 cell cycle arrest in vitro and in vivo. The over-expression of RASSF1A significantly inhibited AP-1 activity in SGC7901 cells (0.981±0.011 vs 0.354±0.053, P<0.001). In addition, both Western blot analysis and immunocytochemistry demonstrated that RASSF1A down-regulated the expression of c-Fos (0.975± 0.02 vs 0.095±0.024, P<0.001) but not c-Jun. CONCLUSION: Over-expression of RASSF1A inhibits the growth of SGC7901 cells by negatively regulating the AP-1 activity, the latter in turn negatively signals cell proliferation.

Role of Activator Protein-1 in the Transcription of Interleukin-5 Gene Regulated by Protein Kinase C Signal in Asthmatic Human TLymphocytes

Summary: In order to explore the role of activator protein-1 (AP-1) in the transcription of interleukin-5 (IL-5) gene regulated by protein kinase C (PKC) signal in peripheral blood T lymphocytes from asthmatic patient, T lymphocytes were isolated and purified from peripheral blood of each asthmatic patient. The T lymphocytes were randomly divided into 4 groups: group A (blank control), group B (treated with PKC agonist phorbol 12-myristate 13-acetate (PMA)), Group C (treated with PMA and AP-1 cis-element decoy oligodeoxynucleotides (decoy ODNs)), and group D (treated with PMA and AP-1 mutant decoy ODNs). The ODNs were transfected into the T cells of group C and D by cation liposome respectively. Reverse transcription-polymerase chain reaction (RT-PCR) was employed to assess IL-5 mRNA expression, and electrophoretic mobility shift assays (EMSA) for the activation of AP-1. The results showed that the activation of AP-1 (88 003.58±1 626.57) and the expression of IL-5 mRNA (0.8300±0.0294) in T lymphocytes stimulated with PMA were significantly higher than these in blank control (20 888.47±1103.56 and 0.3050±0.0208, respectively, P< 0.01), while the indexes (23 219.83±1 024.86 and 0.3425±0.0171 respectively) of T lymphocytes stimulated with PMA and AP-1 decoy ODNs were significantly inhibited, as compared with group B (P< 0.01). The indexes (87 107.41±1 342.92 and 0.8225±0.0222, respectively) in T lymphocytes stimulated with PMA and AP-1 mutant decoy ODNs did not exhibit significant changes, as compared with group B (P>0.05). The significant positive correlation was found between the activation of AP-1 and the expression of IL-5 mRNA (P< 0.01). It was concluded that AP-1 might participate in the signal transduction of PKC-triggered transcription of IL-5 gene in asthmatic T lymphocytes. This suggests the activation of PKC/AP-1 signal transduction cascade of T lymphocytes may play an important role in the pathogenesis of asthma.

Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma

BACKGROUND The clinical effects and detailed roles of long non-coding RNA(LncRNA)steroid receptor RNA activator 1(SRA1)in esophageal squamous cell carcinoma(ESCC)remain ambiguous.In the present study,the complementary sites between lncRNA SRA1,miRNA-363-5p,and phospholysine phosphohistidine inorganic pyrophosphate phosphatase(LHPP)predicted via bioinformatics analysis stimulated us to hypothesize that miRNA-363-5p/LHPP axis might be required for SRA1-mediated ESCC progression.AIM To investigate the molecular events of SRA1 in the malignant behavior in ESCC.METHODS Thirty-eight ESCC tissues and paired adjacent normal tissues were acquired.SRA1 expression was detected in ESCC tissues and cell lines using quantitative reverse transcription-polymerase chain reaction.Cell counting Kit-8 assay,transwell invasion assay,glycolysis assay,and xenograft tumor model were performed to address the malignant biological behaviors of ESCC cells after the introduction of SRA1.The t-test and theχ2 test were used for comparison between groups.Survival curve analysis was performed using the Kaplan-Meier method.RESULTS SRA1 downregulation was identified in ESCC.ESCC patients exhibiting a low SRA1 expression faced shorter overall survival than those with a high SRA1 expression.The introduction of SRA1 inhibited cell proliferation,glucose uptake,and lactate production in ESCC.In vivo,the growth of ESCC was hindered by SRA1 overexpression.Then,SRA1 overexpresses the LHPP by inhibiting miRNA-363-5p.Lastly,the introduction of small interfering RNA si-LHPP or miRNA-363-5p mimic could abrogate the inhibition roles triggered by SRA1.CONCLUSION SRA1 inhibits the oncogenicity of ESCC via miRNA-363-5p/LHPP axis.The SRA1/miRNA-363-5p/LHPP pathway may be a therapeutic target for ESCC.

Diagnostic Value of the Padua Score Combined with Thrombotic Biomarker Tissue Plasminogen Activator Inhibitor-1 (tPAI-1) Detection for the Risk of Deep Vein Thrombosis in Patients with Pulmonary Heart Disease

This study explores the diagnostic value of combining the Padua score with the thrombotic biomarker tissue plasminogen activator inhibitor-1(tPAI-1)for assessing the risk of deep vein thrombosis(DVT)in patients with pulmonary heart disease.These patients often exhibit symptoms similar to venous thrombosis,such as dyspnea and bilateral lower limb swelling,complicating differential diagnosis.The Padua Prediction Score assesses the risk of venous thromboembolism(VTE)in hospitalized patients,while tPAI-1,a key fibrinolytic system inhibitor,indicates a hypercoagulable state.Clinical data from hospitalized patients with cor pulmonale were retrospectively analyzed.ROC curves compared the diagnostic value of the Padua score,tPAI-1 levels,and their combined model for predicting DVT risk.Results showed that tPAI-1 levels were significantly higher in DVT patients compared to non-DVT patients.The Padua score demonstrated a sensitivity of 82.61%and a specificity of 55.26%at a cutoff value of 3.The combined model had a significantly higher AUC than the Padua score alone,indicating better discriminatory ability in diagnosing DVT risk.The combination of the Padua score and tPAI-1 detection significantly improves the accuracy of diagnosing DVT risk in patients with pulmonary heart disease,reducing missed and incorrect diagnoses.This study provides a comprehensive assessment tool for clinicians,enhancing the diagnosis and treatment of patients with cor pulmonale complicated by DVT.Future research should validate these findings in larger samples and explore additional thrombotic biomarkers to optimize the predictive model.

Retinoic acid receptor β is required for anti-activator protein-1 activity by retinoic acid in gastric cancer cells

Objective To investigate the role of retinoic acid receptor β (RARβ) in mediating inhibitory effect of all-trans retinoic acid (ATRA) on activator protein-1 (AP-1) activity in gastric cancer cells. Methods Transient transfection and chloramphenicol acetyltransferase (CAT) assay, Northern blot, gene transfection, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and anchorage-independent growth assay were used.Results Transient transfection of RARβ expression vector into MKN-45 cells resulted in the RARβ concentration-dependent repression of AP-1 activity induced by 12-o-tetradecanoylphorbol-13-acetate (TPA), regardless of the presence of ATRA. When the c-jun and c-fos expression vectors were cotransfected with the RARβ expression vector into MKN-45 cells, AP-1 activity was also obviously repressed. The inhibitory effect, again, was RARβ-concentration-dependent. The stable transfection of the RARβ gene into MKN-45 cells led to cell growth inhibition and colony formation inhibition by ATRA. Furthermore, Cotransfection of both RARβ/DNA binding domain (DBD) and reporter gene could not alter AP-1 activity, even in the presence of ATRA. However, when the cotransfection was substituted with the RARβ/ligand binding domain (LBD), the inhibition was significantly enhanced by ATRA. Conclusion RARβ might be required for anti-AP-1 activity, and contribute to growth inhibition of gastric cancer cells by ATRA.

The action mechanism by which C1q/tumor necrosis factor-related protein-6 alleviates cerebral ischemia/reperfusion injury in diabetic mice

Studies have shown that C1q/tumor necrosis factor-related protein-6 (CTRP6) can alleviate renal ischemia/reperfusion injury in mice. However, its role in the brain remains poorly understood. To investigate the role of CTRP6 in cerebral ischemia/reperfusion injury associated with diabetes mellitus, a diabetes mellitus mouse model of cerebral ischemia/reperfusion injury was established by occlusion of the middle cerebral artery. To overexpress CTRP6 in the brain, an adeno-associated virus carrying CTRP6 was injected into the lateral ventricle. The result was that oxygen injury and inflammation in brain tissue were clearly attenuated, and the number of neurons was greatly reduced. In vitro experiments showed that CTRP6 knockout exacerbated oxidative damage, inflammatory reaction, and apoptosis in cerebral cortical neurons in high glucose hypoxia-simulated diabetic cerebral ischemia/reperfusion injury. CTRP6 overexpression enhanced the sirtuin-1 signaling pathway in diabetic brains after ischemia/reperfusion injury. To investigate the mechanism underlying these effects, we examined mice with depletion of brain tissue-specific sirtuin-1. CTRP6-like protection was achieved by activating the sirtuin-1 signaling pathway. Taken together, these results indicate that CTRP6 likely attenuates cerebral ischemia/reperfusion injury through activation of the sirtuin-1 signaling pathway.

Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma

BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated and it is unknown which factors are related to efficacy.AIM To evaluate the efficacy and independent predictive factors of TACE combined with lenvatinib plus PD-1 inhibitors for unresectable HCC.METHODS This study retrospectively enrolled patients with unresectable HCC who received TACE/lenvatinib/PD-1 treatment between March 2019 and April 2022.Overall survival(OS)and progression-free survival(PFS)were determined.The objective response rate(ORR)and disease control rate(DCR)were evaluated in accordance with the modified Response Evaluation Criteria in Solid Tumors.Additionally,the prognostic factors affecting the clinical outcome were assessed.RESULTS One hundred and two patients were enrolled with a median follow-up duration of 12.63 months.The median OS was 26.43 months(95%CI:17.00-35.87),and the median PFS was 10.07 months(95%CI:8.50-11.65).The ORR and DCR were 61.76%and 81.37%,respectively.The patients with Barcelona Clinic Liver Cancer Classification(BCLC)B stage,early neutrophil-to-lymphocyte ratio(NLR)response(decrease),or early alpha-fetoprotein(AFP)response(decrease>20%)had superior OS and PFS than their counterparts.CONCLUSION This study showed that TACE/lenvatinib/PD-1 treatment was well tolerated with encouraging efficacy in patients with unresectable HCC.The patients with BCLC B-stage disease with early NLR response(decrease)and early AFP response(decrease>20%)may achieve better clinical outcomes with this triple therapy.

Effectiveness and tolerability of programmed cell death protein-1 inhibitor+chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers

BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10.

Diabetes and high-glucose could upregulate the expression of receptor for activated C kinase 1 in retina

BACKGROUND Diabetic retinopathy(DR)is a major ocular complication of diabetes mellitus,leading to visual impairment.Retinal pigment epithelium(RPE)injury is a key component of the outer blood retinal barrier,and its damage is an important indicator of DR.Receptor for activated C kinase 1(RACK1)activates protein kinase C-ε(PKC-ε)to promote the generation of reactive oxygen species(ROS)in RPE cells,leading to apoptosis.Therefore,we hypothesize that the activation of RACK1 under hypoxic/high-glucose conditions may promote RPE cell apoptosis by modulating PKC-ε/ROS,thereby disrupting the barrier effect of the outer blood retinal barrier and contributing to the progression of DR.AIM To investigate the role and associated underlying mechanisms of RACK1 in the development of early DR.METHODS In this study,Sprague-Dawley rats and adult RPE cell line-19(ARPE-19)cells were used as in vivo and in vitro models,respectively,to explore the role of RACK1 in mediating PKC-εin early DR.Furthermore,the impact of RACK1 on apoptosis and barrier function of RPE cells was also investigated in the former model.RESULTS Streptozotocin-induced diabetic rats showed increased apoptosis and upregulated expression of RACK1 and PKC-εproteins in RPE cells following a prolonged modeling.Similarly,ARPE-19 cells exposed to high glucose and hypoxia displayed elevated mRNA and protein levels of RACK1 and PKC-ε,accompanied by an increases in ROS production,apoptosis rate,and monolayer permeability.However,silencing RACK1 significantly downregulated the expression of PKC-εand ROS,reduced cell apoptosis and permeability,and protected barrier function.CONCLUSION RACK1 plays a significant role in the development of early DR and might serve as a potential therapeutic target for DR by regulating RPE apoptosis and barrier function.

白藜芦醇通过调节SIRT1/AMPK信号通路介导自噬反应对膝关节骨性关节炎大鼠细胞凋亡的影响

目的:从沉默信息调节因子1(SIRT1)/腺苷酸活化蛋白激酶(AMPK)信号通路介导自噬角度,探讨白藜芦醇对大鼠膝关节骨性关节炎(KOA)软骨细胞凋亡的影响。方法:50只健康Wistar大鼠随机分为对照组、模型组、白藜芦醇组、白藜芦醇+SIRT1抑制剂组、自噬激活剂组,每组10只。除对照组外其余大鼠均通过注射弗氏完全佐剂造模法复制KOA大鼠模型,白藜芦醇组、白藜芦醇+AMPK抑制剂组、自噬激活剂组分别使用10μmol/kg白藜芦醇、10μmol/kg白藜芦醇+10 mg/kg EX527、2 mg/kg雷帕霉素进行干预,4周后,观察大鼠Lequesne MG膝关节级别;测定大鼠膝关节液中IL-6、肿瘤坏死因子β(TNF-β)水平;HE染色与TUNEL染色观测大鼠膝关节软骨组织形态及凋亡情况;透射电子显微镜观察大鼠软骨细胞自噬情况;Western blot法检测SIRT1、p-AMPK、AMPK、LC3、Beclin-1蛋白表达。结果:与对照组相比,模型组局部反应、步态反应、关节活动、关节肿胀程度加重(P<0.05);与模型组相比,白藜芦醇组、自噬激活剂组局部反应、步态反应、关节活动、关节肿胀程度减轻(P<0.05)。与对照组相比,模型组大鼠软骨组织细胞排列紊乱,粗糙,存在纤维化变性、边缘丘状隆起,细胞器减少,可见空泡变性,自噬小体数目增多,膝关节液IL-6、TNF-β水平、软骨细胞凋亡率、Beclin-1和LC3B/A升高(P<0.05),软骨组织SIRT1、p-AMPK/AMPK降低(P<0.05);与模型组相比,白藜芦醇组、自噬激活剂组大鼠软骨组织细胞排列紊乱、边缘丘状隆起等现象有改善,自噬小体数目增多,膝关节液IL-6、TNF-β水平、软骨细胞凋亡率降低(P<0.05),软骨组织SIRT1、p-AMPK/AMPK、Beclin-1和LC3B/A水平升高(P<0.05);SIRT1抑制剂可逆转白藜芦醇组对大鼠软骨细胞的保护作用。结论:白藜芦醇可能是通过激活SIRT1/AMPK通路介导自噬KOA大鼠软骨细胞凋亡,SIRT1抑制剂可逆转此过程。

Headgear-activator矫治器治疗安氏Ⅱ~1类错的软组织改变

目的:研究Headgear-activator矫治器治疗安氏Ⅱ1类下颌后缩患者软组织侧貌的改变。方法:选择生长发育高峰期的50例安氏Ⅱ1类错患者,分为Headgear-activator矫治器治疗组与对照组,对2组患者治疗前、后拍摄X线头颅定位侧位片,测量所得角度和线距,采用SPSS11.0软件包分别计算均值和标准差,利用配对t检验比较测量指标的变化。结果:鼻唇角、颏唇沟角、Z角增大,H角、上唇和下唇突角、上唇颏突角减小,与对照组比较,差异均有统计学意义(P<0.05)。结论:Headgear-activator矫治器治疗可使软组织颏部前移,上、下唇凸度明显减小,从而改善下颌后缩患者的软组织侧貌。

TRPC1与BK-α的表达对大鼠糖尿病肾病的影响

目的 探究瞬时受体电位C1(transient receptor potential channel 1,TRPC1)蛋白和大电导钙离子激活钾通道α亚单位(large conductance Ca^(2+)-activated K^(+)channel α subunit,BK-α)蛋白对大鼠糖尿病肾病(diabetic kidney disease,DKD)的影响。方法 将SD大鼠随机分为对照组(n=15)和模型组(n=15)。利用高脂饲料和链脲佐菌素(streptozocin,STZ)构建DKD模型。采用血糖分析仪检测大鼠血糖变化;采用全自动生化分析仪检测大鼠肾功能水平;HE染色检测肾组织的病理变化以确定造模成功。实时荧光定量PCR(RT-qPCR)和蛋白免疫印迹分别检测肾组织TRPC1和BK-α的mRNA和蛋白表达水平;免疫组化检测TRPC1和BK-α的分布和表达情况。结果 模型组大鼠空腹血糖(fasting plasma glucose,FPG)、尿白蛋白排泄率(urinary albumin excretion rates,UAER)、血尿素氮(blood urea nitrogen,BUN)和肌酐(creatinine,Cr)均显著高于对照组(P <0.01);模型组大鼠肾小管内壁细胞出现膨胀现象,部分细胞脱离;可见肾小管发生病变或死亡;此外,在许多肾小管及肾间质区域发现有中性白细胞及其残骸;以上HE染色结果提示,DKD模型复制成功。TRPC1和BK-α在肾小球部位最为丰富,且模型组大鼠肾组织中TRPC1和BK-α的mRNA和蛋白水平都显著高于对照组(P <0.05)。结论 大鼠糖尿病肾病影响TRPC1和BK-α在肾组织中的分布和表达。

Head-gear Activator治疗骨性Ⅱ~1类错颌面软、硬组织改变的研究

目的 :通过对Head - gearActivator治疗早期骨性Ⅱ1类错病例矫治前后的X线头影进行测量 ,分析该矫治器对颌骨、牙齿、面型及软组织侧貌的影响。材料与方法 :选择 10名替牙期或恒牙早期的安氏Ⅱ1类错畸形的病例 ,男性 4人 ,女性 6人 ,平均年龄为 11岁。矫治器的设计是参照Graber和VanBeek的设计 ,平均治疗时间为 10 .2个月。选择 33个测量项目进行治疗前后头影测量 ,并运用SAS统计软件对测量结果进行统计分析。结果 :SNA减小 1.17° ,SNB增大 1.16° ,ANB减小 2 .3° :overjet明显减小 6 .0 7°,上下切牙突度减小 ,上前牙舌倾 ,下前牙唇倾 ;全面高及前后下面高均有显著增加 ;面型角和H角减小。说明颌骨、牙齿、面型及软组织侧貌等方面均有明显变化。结论 :Head -gearActivator能有效地达到控制上下颌矢状及垂直方向生长的目的 ,对改善软、硬组织面型。

1-MCP协同活性炭处理抑制鲜切胡萝卜木质化形成研究

鲜切胡萝卜在贮藏过程易发生木质化,导致品质下降。为探究1-MCP协同活性炭处理对鲜切胡萝卜木质化抑制保鲜效果,文章分析了乙烯利、活性炭、1-MCP和1-MCP协同活性炭等4种处理方式对鲜切胡萝卜硬度、总酚、抗氧化性、PPO、POD、PAL和木质素含量的影响。结果表明:1-MCP协同活性炭处理显著延缓了胡萝卜硬度下降;在贮藏第10 d总酚含量达0.20 mg GAE·g^(−1),显著高于其他处理组(P<0.05);抗氧化性也保持最高水平;DPPH自由基清除活性为0.90μmol TE·g^(−1);PPO、POD活性分别为0.23 U·g^(−1)和61.08 U·g^(−1),显著低于对照组(P<0.05);PAL活性和木质素含量分别为81.67 U·g^(−1)和65.88 mg·g^(−1),也显著低于对照组(P<0.05)。可见,1-MCP协同活性炭处理可有效抑制鲜切胡萝卜木质化,提升其贮藏品质。

miR-132-3p/CAMTA1对I-125粒子处理的面神经损伤大鼠施万细胞的调控作用

目的探讨miR-132-3p通过钙调素结合转录因子1(CAMTA1)对I-125粒子处理的面神经损伤大鼠(FNI)中施万细胞的调控作用。方法用I-125粒子辐射大鼠施万细胞,并在细胞中转染miR-132-3p mimic、miR-132-3p inhibitor以及sh-CAMTA1。免疫荧光检测S100B和β-TubulinⅢ荧光强度。RT-qPCR检测miR-132-3p的表达,Western blot检测CAMTA1蛋白表达。EdU染色评估细胞增殖,Transwell检测细胞迁移。同时,构建FNI大鼠模型并在大鼠面部植入I-125粒子,HE、LFB染色以及IF染色评估大鼠面神经组织的病理损伤。StarBase v2.0数据库和双荧光素酶报告实验验证miR-132-3p和CAMTA1的靶向关系。结果S100B和β-TubulinⅢ在大鼠施万细胞中显著表达。I-125粒子辐射组中miR-132-3p表达降低(P<0.001),抑制细胞的增殖(P<0.001)和迁移(P<0.001)。过表达miR-132-3p或敲降CAMTA1显著促进施万细胞的增殖(P<0.001)和迁移(P<0.05),敲降miR-132-3p则具有相反的作用。机制研究显示,miR-132-3p靶向负调控CAMTA1。体内实验结果显示,过表达miR-132-3p通过抑制CAMTA1的蛋白表达,减弱I-125粒子对FNI大鼠面神经损伤的促进作用。结论过表达miR-132-3p抑制CAMTA1的表达,促进施万细胞的增殖和迁移,抑制I-125对FNI大鼠面神经损伤的促进作用。

阿江榄仁酸由AMPK/mTOR/HO-1信号通路调控自噬对糖尿病视网膜病变影响

目的探讨阿江榄仁酸(arjunolic acid,AA)对糖尿病视网膜病变(diabetic retinopathy,DR)大鼠视网膜细胞自噬及AMPK/mTOR/HO-1信号通路的影响。方法以健康SD大鼠为研究对象,构建链脲佐菌素(STZ)诱导的糖尿病大鼠模型,随机分为对照组(Con)组、模型(STZ)组、AA低剂量(AAL,10 mg/kg)组和AA高剂量(AAH,10 mg/kg)组。连续给药10周后,HE染色检测视网膜组织病理结构;qRT-PCR检测视网膜组织白介素(IL)-1β、IL-6和线粒体丙酮酸转运载体(MPC)-1的mRNA表达;二氢乙锭(DHE)染色评估视网膜组织ROS产生;Western blot检测自噬和AMPK/mTOR/HO-1信号通路相关蛋白表达。结果与Con组比较,STZ组大鼠视网膜出现肿胀和空泡样变化等病理变化,中央视网膜ONL层厚度和细胞核计数明显降低(P<0.01);IL-1β、IL-6和MCP-1的mRNA水平显著增高(P<0.05);视网膜外核层(ONL)、内核层(INL)和神经节细胞层(GCL)中ROS产生增加(P<0.01);LC3II/I比率、HO-1和p-AMPK/AMPK蛋白表达显著降低,p62和p-mTOR/mTOR表达升高(P<0.01)。与STZ组比较,AAL和AAH组大鼠视网膜ONL厚度和细胞核计数逐渐升高,结构相对规整(P<0.05);AAH组IL-1β、IL-6和MCP-1的mRNA表达明显降低(P<0.05);视网膜ONL、INL和GCL中ROS产生逐渐降低(P<0.01);LC3II/I比率、p-AMPK/AMPK和HO-1表达逐渐升高,p62和p-mTOR/mTOR表达逐渐降低(P<0.01)。结论阿江榄仁酸可能是治疗DR的候选药物,可能机制为通过AMPK/mTOR/HO-1调节的自噬途径保护视网膜细胞免受STZ诱导的氧化应激和炎症损伤。

血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6在结核性胸膜炎胸膜纤维化患者中的变化及临床意义

目的探讨血清和胸腔积液纤溶酶原激活剂抑制物-1(PAI-1)、转化生长因子-β(TGF-β)、血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)在结核性胸膜炎胸膜纤维化患者中的变化及临床意义。方法选取2020年7月至2023年7月该院收治的103例结核性胸膜炎胸膜纤维化患者作为研究对象,治疗2周后,根据糖皮质激素治疗疗效将其分为显效组、非显效组。比较两组治疗前及治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平。采用Spearman相关分析血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效的相关性。治疗2周后血清PAI-1、TGF-β、VEGF、IL-6水平与胸腔积液中该指标水平之间进行Pearson相关分析。绘制受试者工作特征曲线分析治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平对结核性胸膜炎胸膜纤维化患者疗效的预测价值。结果两组治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平低于治疗前,显效组治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平低于非显效组,差异有统计学意义(P<0.05)。治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效呈负相关(P<0.05)。治疗2周后血清PAI-1、TGF-β、VEGF、IL-6水平和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平呈正相关(r=0.761、0.783、0.812、0.741,均P<0.05)。治疗1、2周后血清和胸腔积液各指标联合检测的曲线下面积(AUC)大于其单独指标的AUC(P<0.05)。结论结核性胸膜炎胸膜纤维化患者血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效有关,血清及胸腔积液PAI-1、TGF-β、VEGF、IL-6联合检测的预测价值较好,能够为临床干预提供参考依据。

冬凌草甲素调节JAK2/STAT3/SOCS-1信号通路对糖耐量异常大鼠胰岛素抵抗的影响

目的探讨冬凌草甲素(Oridonin,Ori)对糖耐量异常(impaired glucose tolerance,IGT)大鼠胰岛素抵抗(insulin resistance,IR)的影响及作用机制。方法采用高脂饮食喂养联合链脲佐菌素注射法构建IGT大鼠IR模型,大鼠分为正常组(CT组)、IGT模型组(IGT组)、Ori组(10 mg·kg^(-1)·d^(-1))、Ori+Colivelin(COL)组(10 mg·kg^(-1)·d^(-1)Ori+2 mg/kg COL),每组6只。血糖检测仪测定空腹血糖(FPG)、葡萄糖耐量试验(OGTT)2 h血糖(2 hPG),ELISA试剂盒测定空腹胰岛素(FINS)、单核细胞趋化蛋白1(MCP-1)、肿瘤坏死因子α(TNF-α)含量,计算胰岛素抵抗指数(HOMA-IR),血液自动分析仪测定血清胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平,HE染色观察肝脏病理形态,Western blot验证附睾脂肪磷酸化(p)-激活Janus激活激酶2(JAK2)、JAK2、p-信号转导和转录激活因子3(STAT3)、STAT3、p-细胞因子信号传导抑制蛋白1(SOCS-1)、SOCS-1蛋白表达。结果与CT组比较,IGT组大鼠肝脏细胞肿胀,胞浆内可见大量大小不一的脂肪空泡,细胞核被脂肪空泡挤压偏位,且发生炎性细胞浸润,FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α以及p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1蛋白表达水平升高,血清HDL-C水平下降(P<0.05);与IGT组相比,Ori组大鼠肝脏细胞胞浆内脂肪滴及空泡数量明显减少,细胞肿胀有所缓解,未见炎性细胞浸润,FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α以及p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1蛋白表达水平下降,血清HDL-C水平升高(P<0.05);与Ori组相比,Ori+COL组大鼠肝脏脂肪变状况加剧,细胞肿大,血清FPG、2hPG、FINS、HOMA-IR、TC、TG、LDL-C、MCP-1、TNF-α以及p-JAK2/JAK2、p-STAT3/STAT3、p-SOCS-1/SOCS-1蛋白表达水平升高,血清HDL-C水平下降(P<0.05)。结论Ori对IGT大鼠IR的缓解作用可能与抑制JAK2/STAT3/SOCS-1信号通路激活有关。

超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析

目的分析超声衰减参数(UAP)联合血清纤溶酶原激活物抑制物1(PAI-1)和丙氨酸氨基转移酶(ALT)水平评估代谢相关性脂肪性肝病(MAFLD)患者肝脂肪变性程度的效能。方法2019年3月~2022年12月我院诊治的112例MAFLD患者均接受肝穿刺活检,所有受试者接受iLivTouch瞬时弹性成像检测UAP,采用ELISA法检测血清PAI-1水平,应用受试者工作特征(ROC)曲线分析UAP联合血清PAI-1和ALT水平评估MAFLD患者肝脂肪变性程度的效能。结果在112例MAFLD患者中,经肝组织病理学检查发现肝脂肪变1级(轻度)45例,2级(中度)42例和3级(重度)25例;重度肝脂肪变患者BMI、血清TC、TG和LDL-C水平分别为(32.6±2.4)kg/m^(2)、(6.6±0.9)mmol/L、(4.6±1.4)mmol/L和(4.0±0.9)mmol/L,显著高于中度患者【分别为(27.6±1.9)kg/m^(2)、(5.8±0.8)mmol/L、(3.5±0.9)mmol/L和(3.5±0.7)mmol/L,P<0.05】或轻度患者【分别为(24.1±0.9)kg/m^(2)、(5.1±0.7)mmol/L、(2.2±0.7)mmol/L和(3.0±0.5)mmol/L,P<0.05】,而血清HDL-C水平为(1.2±0.2)mmol/L,显著低于中度【(1.4±0.2)mmol/L,P<0.05】或轻度患者【(1.4±0.2)mmol/L,P<0.05】;重度组UAP、血清PAI-1和ALT水平分别为(312.7±32.6)dB/m、(36.5±4.2)mg/mL和(72.1±7.4)U/L,显著高于中度组【分别为(284.2±30.1)dB/m、(28.1±3.4)mg/mL和(36.3±4.1)U/L,P<0.05】或轻度组【分别为(257.4±26.4)dB/m、(20.4±2.4)mg/mL和(23.7±2.5)U/L,P<0.05】;ROC曲线分析显示,UAP联合血清PAI-1和ALT水平评估重度肝脂肪变性的曲线下面积(AUC)、特异度和敏感度分别为0.914(95%CI:0.883~0.990)、89.6%和93.3%,其特异度显著优于单一指标预测(P<0.05)。结论应用UAP联合血清PAI-1和ALT水平预测MAFLD患者严重肝脂肪变性有良好的评估价值,可为临床诊治提供参考依据。

PAI-1、Hcy水平与妊娠合并心脏病患者妊娠结局的相关性分析

目的探讨纤溶酶原激活物抑制物-1(PAI-1)、同型半胱氨酸(Hcy)水平与妊娠合并心脏病患者妊娠结局的相关性。方法选取2020年1月至2023年1月我院收治的80例合并心脏病的孕妇作为研究组,另选取同期产检健康孕妇80例作为对照组,比较研究组与对照组PAI-1、Hcy水平。将研究组患者根据妊娠结局分为妊娠不良组22例和妊娠良好组58例,比较两组临床资料、三酰甘油(TG)、总胆固醇(TC)、PAI-1、Hcy水平;相关性采用Spearman秩相关分析检验;多因素分析采取二元Logistics回归分析;绘制ROC曲线,分析血清PAI-1、Hcy水平预测不良妊娠结局的价值。结果研究组PAI-1、Hcy水平显著高于对照组(P<0.05);妊娠不良组和妊娠良好组年龄、产次、孕周、分娩孕周、心脏病类型、心功能分级、TC、TG比较差异无统计学意义(P>0.05),妊娠不良组PAI-1、Hcy水平显著高于妊娠良好组(P<0.05);妊娠合并心脏病患者血清PAI-1、Hcy水平与不良妊娠结局呈正相关(P<0.05);多因素Logistic回归分析显示,PAI-1及Hcy为妊娠合并心脏病患者不良妊娠结局的显著影响因素;经ROC分析发现PAI-1、Hcy水平可用于妊娠合并心脏病患者不良妊娠结局的预测,曲线下面积为0.810、0.817,联合预测曲线下面积为0.918。结论妊娠合并心脏病患者血清PAI-1、Hcy水平显著增加孕妇不良妊娠结局发生率,上述指标与不良妊娠结局显著相关,其水平是不良妊娠结局的影响因素,并可用于不良妊娠结局预测,联合预测价值更高。